Skip to content

CNTN CNTN Accounts Payable

Accounts Payable at other companies

Regenxbio logo
RegenxbioRGNX

Other financials

Income statement

See full
Operating income-$36.9M-1,348%
Net income-$47.3M-1,763%
EPS (diluted)-$0.23+76.8%

Balance sheet

See full
Cash & equivalents$41.5M+3,760%
Total debt$1.4M0.0%
Total equity$469.8M+57,767%
Total assets$584.7M+35,093%

Cash flow

See full
Operating cash flow-$7.6M-184%

Valuation

See full
Market cap$217.49M+8.0%

Returns & leverage

See full
Return on equity-18%-8.6pp
Debt / equity0.3×
Current ratio37.7×+37.1×

Where this comes from

Reported directly by CNTN in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: CNTN’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about CNTN's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CNTN's accounts payable?
CNTN (CNTN) reported accounts payable of -$687.96K in Q1 2026.
How has CNTN's accounts payable changed year-over-year?
CNTN's accounts payable decreased by 1192.0% year-over-year, from $63K to -$687.96K.
What is the long-term trend for CNTN's accounts payable?
Over 2 years (2023 to 2025), CNTN's accounts payable has grown at a 120.1% compound annual growth rate (CAGR), from -$45.93K to $222.48K.